Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
What is the purpose of this trial?
This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous PD-L1 positive NSCLC.
- Trial withYale Cancer Center
- Start Date03/03/2022
- End Date02/01/2025
- Last Updated11/11/2022
- Study HIC#2000030093